Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06085833 · ClinicalTrials.gov registry record · NA
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
A NA study of Breast Cancer, sponsored by ARTIDIS.
- Recruiting
- Registry status
- NA
- Development phase
- 2,706
- Enrollment target
- 5
- Study locations
NCT06085833: Recruiting NA study of Breast Cancer, sponsored by ARTIDIS.
NCT06085833 is a NA study of Breast Cancer that is actively recruiting participants, run by ARTIDIS. The registered enrollment target is 2,706 participants, roughly in line with the 2,801-participant average among 1,224 other Breast Cancer trials with a reported enrollment target. The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06085833, a NA study of Breast Cancer, is actively recruiting participants, sponsored by ARTIDIS.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,706 participants
- Enrollment target
- 5
- Study locations
Study Summary
This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the gold standard of histopathological assessment. The study involves patients with suspicious breast lesions who will undergo a breast biopsy procedure indicated by standard of care. The nanomechanical phenotype will be measured on the freshly obtained breast biopsies or tissue from breast surgeries.
Primary Outcome
Variable, indicating a correct classification of patients' core biopsy material as malignant with the Nanomechanical Phenotype measurement in comparison to histopathological assessment as gold-standard.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Nanomechanical Phenotype Test
Study Locations (5)
Texas
- University of Texas Southwestern Medical Center - Dallas
- Baylor College of Medicine - Houston
- MD Anderson Cancer Clinic - Mays Clinic - Houston
Barcelona
- Hospital Universitario Vall d'Hebron - Barcelona
Basel
- Claraspital - Basel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,706 participants |
| Start Date | 2023-11-02 |
| Est. Completion | 2035-11 |
| Phase | NA |
What NCT06085833 shows while recruiting
NCT06085833 is an interventional study that assigns participants to a tested intervention. Its 2,706 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 2,801-participant average among 1,224 other Breast Cancer trials with a reported enrollment target.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Nanomechanical Phenotype Test is the first listed.
NCT06085833 lists 5 locations in 3 states (Texas, Barcelona, Basel).
Frequently Asked Questions
What is clinical trial NCT06085833 about?
NCT06085833 is a clinical study titled "ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions". This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the gold standard of histopathological assessment. The study involves patients with suspicious breast le...
What is the current status of trial NCT06085833?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,706 participants. The study started on 2023-11-02. Estimated completion is 2035-11.
What conditions does trial NCT06085833 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT06085833?
The interventions under investigation include: Nanomechanical Phenotype Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06085833?
This trial is sponsored by ARTIDIS, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06085833 being conducted?
This trial has 5 study locations across Texas, Barcelona, Basel. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06085833's enrollment target sits among peer trials
2,706 53rd of 1224 higher than 1,172 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
- NCT05586776 · 2,700 participants · Phase 4
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
- NCT06052267 · 2,700 participants · Phase 3
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI